Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19388156 | 1.00 | MEN1 (0.42) | MEN1TSHRHTTKMT2ASMN1; SMN2 | |
| SCHEMBL21030358 | 1.00 | MEN1 (0.42) | MEN1TSHRHTTKMT2ASMN1; SMN2 | |
| SCHEMBL8370472 | 0.87 | NR1I2 (0.41) | TSHRNR1I2LMNASLC2A1CSNK1E | |
| SCHEMBL22795551 | 0.85 | GABBR2 (0.46) | MEN1TSHRHTTKMT2ASMN1; SMN2 | |
| SCHEMBL21726771 | 0.84 | MEN1 (0.44) | MEN1TSHRHTTKMT2ASMN1; SMN2 | |
| SCHEMBL27422072 | 0.80 | NR1I2 (0.37) | HTTKMT2ANR1I2LMNASLC2A1 | |
| SCHEMBL20372803 | 0.80 | NR1I2 (0.37) | HTTKMT2ANR1I2LMNASLC2A1 | |
| SCHEMBL28288142 | 0.79 | NR1I2 (0.46) | NR1I2LMNASLC2A1CSNK1E | |
| SCHEMBL20372927 | 0.77 | NR1I2 (0.36) | NR1I2LMNASLC2A1CSNK1E | |
| SCHEMBL28224807 | 0.77 | NR1I2 (0.44) | NR1I2LMNASLC2A1CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | ADORA3, ADORA2B, ADORA1 | MEN1 3492/4885TSHR 289/4885HTT 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.